NSAIDs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Molecule Type (Ibuprofen, Aspirin, Paracetamol, Diclofenac and Diclofenac Others), By Formulation (Tablets, Capsules, Suspension, Topical Preparations and Others), and Region Forecast 2019-2030    

Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market size was valued at US$ 2,603 million in 2023 and is poised to grow at a significant CAGR of 0.8% from 2024-2030. Patients with chronic inflammatory arthritis frequently take nonsteroidal anti-inflammatory drugs (NSAIDs). The market for NSAIDs is expected to grow faster as the incidence of arthritis rises. Because of their ability to block prostaglandin formation at the level of the cyclooxygenase enzyme, they are powerful anti-inflammatory and analgesic. In January 2021, NSAIDs have several medications on the market, with many more in the works. Celebrex, an oral drug intended to treat inflammation and discomfort caused by ankylosing spondylitis and other illnesses, was approved by the US Food and Drug Administration. Osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea are among the conditions for which the generic medication is prescribed.

For instance, According to the Centers for Disease Control and Prevention (CDC), from 2013-2015, approximately 54.4 Mn US adults had some form of arthritis such as gout, rheumatoid arthritis treatment, fibromyalgia, and lupus, and estimated to reach 78 Mn adults aged 18 years older are projected to have arthritis by 2040.  NSAIDs are a drug class that groups together drugs that provide analgesic and antipyretic effects.

Moreover, increasing access to healthcare with the rapid penetration of technology and other developments in the healthcare sector has increased the consumption of drugs, thereby directly creating positive impact on the NSAID market. However, the availability of alternative products in the market for NSAIDs and the development of advanced medications are expected to hamper the growth of the market. 

Key Developments

• In May 2019, according to Perrigo Company plc, the FDA has approved an Abbreviated New Drug Application (ANDA) for Voltaren Gel.
• In April 2018: The USFDA authorized Strides Shasun's generic Ibuprofen capsules, 200 mg. They are intended to alleviate pain. Pfizer Inc.'s Advil Liqui-Gels 200 mg is a generic version.